 EMERYVILLE, Calif., Oct. 28, 2020 GLOBE NEWSWIRE -- XOMA Corporation Nasdaq: XOMA announced today NIS793, an anti-TGFβ monoclonal antibody licensed from XOMA, has advanced to the Phase 2 development stage, triggering a 25 million milestone payment from Novartis. The Phase 2 trial NCT04390763 is designed to assess the efficacy and safety of NIS793 in first-line metastatic pancreatic ductal adenocarcinoma mPDAC. 